GlassScriptPhysician profile
Megan Brown
NPI 1336754167
$4,649.70
in general payments reported to CMS, 2019-2025
38 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $821 · 2023: $777 · 2024: $1,200 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.33 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $568.09 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $553.29 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $378.15 | 2022-2025 | |
| Axsome Therapeutics, INC. | $274.65 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Corcept Therapeutics | $221.54 | 2022-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $210.94 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.11 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $148.32 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $126.32 | 2021-2025 | Mounjaro, Zepbound, Reyvow |
| Abbvie INC. | $120.32 | 2024-2025 | |
| Glaxosmithkline, LLC. | $104.69 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $103.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $73.45 | 2021-2022 | |
| Viatris Specialty LLC | $72.60 | 2025 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $69.52 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $67.13 | 2021-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $66.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.25 | 2023-2025 | Belsomra, Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $58.20 | 2021-2023 | |
| Amgen INC. | $58.19 | 2022-2024 | Prolia, Evenity |
| Eisai INC. | $55.13 | 2021 | |
| Antares Pharma, INC. | $50.74 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $49.61 | 2021-2025 | Veozah |
| Dexcom, INC. | $42.77 | 2021-2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $42.14 | 2022 | |
| Corium, LLC | $38.19 | 2023 | Azstarys |
| Amarin Pharma, INC. | $33.49 | 2021 | |
| Inspire Medical Systems, INC. | $28.42 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $25.32 | 2022 | |
| Insulet Corporation | $24.07 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $23.98 | 2024 | Camzyos |
| Impel Pharmaceuticals LLC | $21.33 | 2024 | Trudhesa |
| Impel Pharmaceuticals INC. | $19.03 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $18.50 | 2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $16.30 | 2021 | |
| Exact Sciences Corporation | $14.56 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.